Endovascular Stenting in 2 Patients with Benign Superior Vena Cava Syndrome

Hooker, Jared B; Hawkins, Beau M.; Abu‐Fadel, Mazen

doi:10.14503/thij-17-6263

Cited by 6 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical findings classically described include facial, periorbital, cervical, and upper limb edemas followed by venous dilatations of the anterior thoracic wall, characterizing collateral circulation. Although it is usually not life threatening, SVCS is frequently associated with uncomfortable symptoms, such as dyspnea, dysphagia, and cognitive alterations, and intracranial venous hypertension can result in coma 6…”

Section: Introductionmentioning

confidence: 99%

Superior vena cava syndrome: endovascular management

Karakhanian

Belczak

2019

J. vasc. bras.

View full text Add to dashboard Cite

BackgroundThe objective of management of superior vena cava syndrome (SVCS) is to promptly alleviate the uncomfortable symptoms. Conventional approaches do not always achieve results as rapidly as endovascular management with stent placement.ObjectivesTo report the experience with endovascular management of SVCS of a Vascular and Endovascular Surgery Service at a Brazilian university hospital.MethodsSymptomatic type III SVCS cases were managed with angioplasty and stent placement in 28 patients aged from 37 to 68 years, between 2002 and 2012. The etiology of SVCS was lung or thoracic cancer in 18 patients, while occlusion of the vein for prolonged use of catheters was the cause in the other 10 cases.ResultsSuperior vena cava occlusion repair was not possible in one oligosymptomatic patient with a very severe lesion. Technical success was achieved in 96.4%. There were two deaths, one due to pulmonary embolism, 24 hours after a successful procedure, and the other due to compression of the airways by tumor mass some hours after the procedure. Clinical success was achieved in all cases of technical success, including one patient who died suddenly, after total regression of SVCS symptoms. Symptoms disappeared 24 hours and 48 hours after management in16 and 8 patients respectively; improvement was slower but progressive after 48 hours in the remaining patients.ConclusionsEndovascular stent placement was effective for management of SVCS, with good technical and clinical success rates and provided prompt relief from symptoms.

show abstract

Section: Introductionmentioning

confidence: 99%

Superior vena cava syndrome: endovascular management

Karakhanian

Belczak

2019

J. vasc. bras.

View full text Add to dashboard Cite

show abstract

“…As more patients undergo treatment with indwelling catheters, and potentially longer dwell times, the incidence of SVC syndrome is expected to increase. 4…”

Section: Introductionmentioning

confidence: 99%

Endovascular Treatment of Superior Vena Cava Syndrome : A Systematic Review

Atin,

Prasetyanto,

Johana Tiluata

et al. 2023

JARMHS

View full text Add to dashboard Cite

Background: Endovascular stenting has been used to manage superior vena cava syndrome for several decades and has become standard firstline practice. Superior vena cava (SVC) syndrome is caused by the obstruction of the SVC and can result in significant morbidity and mortality. Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020, this study was able to show that it met all of cthe requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2013 and 2023 were taken into account. Several different online reference sources, like Pubmed and SagePub, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done. Result: In the PubMed database, the results of our search brought up 292 articles, whereas the results of our search on SagePub brought up 315 articles. The results of the search conducted for the last year of 2013 yielded a total 163 articles for PubMed and 127 articles for SagePub. In the end, we compiled a total of 6 papers, 4 of which came from PubMed and 2 of which came from SagePub. We included six research that met the criteria. Conclusion: In summary, this review confirms the effectiveness of endovascular stenting in managing SVCS. Further directions of research may include specific outcomes of endovascular stenting in benign SVCS, and the impact of procedural characteristics, such as the use of anticoagulation and type of stent used, on outcomes.

show abstract

“…Optimal treatment of device-related SVC syndrome is not well defined, but ET remains a viable first option as it does not preclude or affect the outcome of potential open surgical bypass in the future [12] . As more patients undergo treatment with indwelling catheters, and potentially longer dwell times, the incidence of SVC syndrome is expected to increase [13] .…”

Section: Introductionmentioning

confidence: 99%

Endovascular therapy for superior vena cava syndrome: A systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Background: Superior vena cava (SVC) syndrome is caused by the obstruction of the SVC and can result in significant morbidity and mortality. In contemporary practice, endovascular therapy (ET) has become the standard of care for a majority of these patients. This study is a systematic review and meta-analysis of the available literature to assess technical success, restenosis, and recurrence of SVC syndrome following endovascular intervention. Methods: For this meta-analysis, we conducted a systematic literature review of PubMed, Cochrane Library, and Embase databases from inception to April 14, 2021 for studies on ET for SVC syndrome. Studies included full-length journal articles on the use of ET among adults with SVC syndrome. Case reports or case series with fewer than 20 patients were excluded. We evaluated the endpoints of technical success rate, restenosis rate, and recurrence rates in SVC syndrome patients after endovascular stenting. The results of this study were calculated using random-effects models. Findings: We identified 6,012 reports, of which 39 studies met our inclusion criteria and were included for analysis. A total of 2200 patients received ET for SVC syndrome. The weighted technical success rate was 98.8% (95% CI 98.2À99.3) with low heterogeneity (I 2 =17.4%, p = 0.185), restenosis rate was 10.5% (95% CI 8.4À12.6) with moderate heterogeneity (I 2 =53.5%, p<0.001), and recurrence rate was 10.8% (95% CI 8.1À13.5) with high heterogeneity (I 2 =75.8%, p<0.001). Total complication rate was 8.6% (95% CI 7.3%-9.9%) with a mean complication rate of 7.5% (95% CI 4.7%-10.3%). Interpretation: Our systematic review revealed high technical success, low restenosis, and low recurrence rates following ET. Collectively, these results support the paradigm of ET as an effective and safe treatment for patients with SVC syndrome.

show abstract

Endovascular Stenting in 2 Patients with Benign Superior Vena Cava Syndrome

Cited by 6 publications

References 15 publications

Superior vena cava syndrome: endovascular management

Superior vena cava syndrome: endovascular management

Endovascular Treatment of Superior Vena Cava Syndrome : A Systematic Review

Endovascular therapy for superior vena cava syndrome: A systematic review and meta-analysis

Contact Info

Product

Resources

About